Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Chase et al. Supplementary Appendix

Chase et al. Supplementary tables provided by the authors.

Files in this Data Supplement:

• Adobe PDF - 2012.067959.CHASE_SUPPL.pdf